Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.73 |
| ▸ | TPSAB1 | Q15661 | 6/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | TRPC6 | Q9Y210 | 4/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4722167 | 0.99 | CYP3A4 (0.75) | CYP3A4CYP2D6KCNH2TPSAB1CYP2C9 | |
| SCHEMBL10358989 | 0.93 | CYP3A4 (0.66) | CYP3A4CYP2D6KCNH2TPSAB1CYP2C9 | |
| SCHEMBL18652766 | 0.88 | CYP3A4 (0.60) | CYP3A4CYP2D6KCNH2TPSAB1CYP2C9 | |
| SCHEMBL18652767 | 0.87 | CYP3A4 (0.61) | CYP3A4CYP2D6KCNH2TPSAB1CYP2C9 | |
| SCHEMBL12446414 | 0.87 | CYP3A4 (1.00) | CYP3A4CYP2D6KCNH2TPSAB1CYP2C9 | |
| SCHEMBL4975268 | 0.86 | CYP3A4 (0.59) | CYP3A4CYP2D6KCNH2TPSAB1CYP2C9 | |
| Hydrochloric Acid SCHEMBL2222439 | 0.86 | CYP3A4 (0.98) | CYP3A4CYP2D6KCNH2TPSAB1CYP2C9 | |
| SCHEMBL5226449 | 0.85 | CYP3A4 (0.57) | CYP3A4CYP2D6KCNH2TPSAB1CYP2C9 | |
| SCHEMBL12516679 | 0.84 | CYP3A4 (0.72) | CYP3A4CYP2D6KCNH2TPSAB1CYP2C9 | |
| Hydrochloric Acid SCHEMBL2271590 | 0.81 | CYP3A4 (0.79) | CYP3A4CYP2D6KCNH2TPSAB1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008121666-A1 | USE OF 4-BROMO-3-METHYL-5-PROPOXYTHIOPHENE-2-CARBOXYLIC ACID 2,5-DIOXO-PYRROLIDIN-1-YL ESTER FOR PREPARING THE TRYPTASE INHIBITOR [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | claimed |
| EP-2483243-B1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2015-03-18 | — | — | EP | disclosed |
| US-8633321-B2 | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof | SANOFI-AVENTIS U.S. LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633321-B2 | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof | SANOFI-AVENTIS U.S. LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120184745-A1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184745-A1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2011037947-A1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2011-03-31 | — | — | WO | disclosed |
| EP-2001839-A1 | IMPROVEMENTS IN THE PREPARATION OF INTERMEDIATES LEADING TO [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2YL)-METHANONE HYDROCHLORIDE | Sanofi-Aventis (FR) | 2008-12-17 | — | — | EP | disclosed |
| EP-2001839-A1 | IMPROVEMENTS IN THE PREPARATION OF INTERMEDIATES LEADING TO [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2YL)-METHANONE HYDROCHLORIDE | Sanofi-Aventis (FR) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008121666-A1 | USE OF 4-BROMO-3-METHYL-5-PROPOXYTHIOPHENE-2-CARBOXYLIC ACID 2,5-DIOXO-PYRROLIDIN-1-YL ESTER FOR PREPARING THE TRYPTASE INHIBITOR [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008121666-A1 | USE OF 4-BROMO-3-METHYL-5-PROPOXYTHIOPHENE-2-CARBOXYLIC ACID 2,5-DIOXO-PYRROLIDIN-1-YL ESTER FOR PREPARING THE TRYPTASE INHIBITOR [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008121669-A1 | 4-BROMO-3-METHYL-5-PROPOXYTHIOPHENE-2-CARBOXYLIC ACID 2,5-DIOXO-PYRROLIDIN-1-YL ESTER, ITS REGIO-SPECIFIC SYNTHESIS AND INTERMEDIATE THERETO | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008115912-A1 | REGIO-SPECIFIC SYNTHESIS OF 4-BROMO-3-METHYL-5-PROPOXY-THIOPHENE-2-CARBOXYLIC ACID | SANOFI-AVENTIS (FR) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007118010-A1 | IMPROVEMENTS IN THE PREPARATION OF INTERMEDIATES LEADING TO [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2YL)-METHANONE HYDROCHLORIDE | SANOFI-AVENTIS (FR) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007118010-A1 | IMPROVEMENTS IN THE PREPARATION OF INTERMEDIATES LEADING TO [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2YL)-METHANONE HYDROCHLORIDE | SANOFI-AVENTIS (FR) | 2007-10-18 | — | — | WO | disclosed |
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1737848-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | Aventis Pharmaceuticals Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005097780-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097780-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | CMA1, TPSAB1, TPSB2 | CYP3A4 298/4885CYP2D6 59/4885KCNH2 677/4885 |
| US-20120184745-A1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | TBC1D5, TBC1D15, TERT | CYP3A4 56/4885CYP2D6 227/4885KCNH2 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.